Literature DB >> 8889174

Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region.

P C Keck1, J S Huston.   

Abstract

Molecular modeling studies on antibody Fv regions have been pursued to design a second antigen-binding site (chi-site) in a chimeric single-chain Fv (chi sFv) species of about 30 kDa. This analysis has uncovered an architectural basis common to many Fv regions that permits grafting a chi-site onto the Fv surface that diametrically opposes the normal combining site. By using molecular graphics analysis, chimeric complementarity-determining regions (chi CDRs) were defined that comprised most of the CDRs from an antibody binding site of interest. The chain directionality of chi CDRs was consistent with that of specific bottom loops of the sFv, which allowed for grafting of chi CDRs with an overall geometry approximating CDRs in the parent combining site. Analysis of 10 different Fv crystal structures indicates that the positions for inserting chi CDRs are very highly conserved, as are the corresponding chi CDR boundaries in the parent binding site. The results of this investigation suggest that it should be possible to generally apply this approach to the development of chimeric bispecific antibody binding site (chi BABS) proteins.

Mesh:

Substances:

Year:  1996        PMID: 8889174      PMCID: PMC1233666          DOI: 10.1016/S0006-3495(96)79398-0

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  43 in total

1.  Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A.

Authors:  Y Satow; G H Cohen; E A Padlan; D R Davies
Journal:  J Mol Biol       Date:  1986-08-20       Impact factor: 5.469

2.  The Protein Data Bank: a computer-based archival file for macromolecular structures.

Authors:  F C Bernstein; T F Koetzle; G J Williams; E F Meyer; M D Brice; J R Rodgers; O Kennard; T Shimanouchi; M Tasumi
Journal:  J Mol Biol       Date:  1977-05-25       Impact factor: 5.469

3.  Reshaping human antibodies: grafting an antilysozyme activity.

Authors:  M Verhoeyen; C Milstein; G Winter
Journal:  Science       Date:  1988-03-25       Impact factor: 47.728

4.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

5.  Three-dimensional structure of the Fab' fragment of a human immunoglobulin at 2,8-A resolution.

Authors:  R J Poljak; L M Amzel; H P Avey; B L Chen; R P Phizackerley; F Saul
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

6.  Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers.

Authors:  J Novotný; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

7.  Molecular anatomy of the antibody binding site.

Authors:  J Novotný; R Bruccoleri; J Newell; D Murphy; E Haber; M Karplus
Journal:  J Biol Chem       Date:  1983-12-10       Impact factor: 5.157

Review 8.  Three-dimensional structure of immunoglobulins.

Authors:  L M Amzel; R J Poljak
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

9.  Assembly of a functional immunoglobulin Fv fragment in Escherichia coli.

Authors:  A Skerra; A Plückthun
Journal:  Science       Date:  1988-05-20       Impact factor: 47.728

Review 10.  Antigen recognition and targeted delivery by the single-chain Fv.

Authors:  J S Huston; M S Tai; J McCartney; P Keck; H Oppermann
Journal:  Cell Biophys       Date:  1993 Jan-Jun
View more
  2 in total

1.  A relation between the principal axes of inertia and ligand binding.

Authors:  J Foote; A Raman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 2.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.